Beissova Ainagul, Kamkhen Vitaly, Turbekova Mira, Malgazhdarov Maulen, Koshkimbayeva Sabira, Kozhabek Lyaila
al-Farabi Kazakh National University, Almaty, Kazakhstan.
Department of Epidemiology, Biostatistics and Evidence-Based Medicine, al-Farabi Kazakh National University, Almaty, Kazakhstan.
Med J Islam Repub Iran. 2023 Apr 10;37:35. doi: 10.47176/mjiri.37.35. eCollection 2023.
During the COVID-19 pandemic, patients with diabetes are among the most vulnerable. Our purpose is to research the dynamics of morbidity, mortality, and survival of patients with diabetes in Kazakhstan before and during the current pandemic.
The indicators were calculated taking into account gender and nosological forms (E10-E14, according to ICD-10).The survival analysis was performed by the method of constructing survival tables and the Kaplan-Meier method. Based on methods, the official reporting data of 1,903,243 cases of diabetes and 20,605 deaths from diabetes were analyzed for the period 2018-2021.
In Kazakhstan, during the COVID-19 pandemic, there has been an increase in the absolute frequency of all cases of diseases by 1.8 times (716,048 in 2021 against 396,990 in 2018) and newly detected by 2.0 times (from 38,396 to 75,027), also prevalence by 1.7 times (3743.9 in 2021 against 2142.2 in 2018) and incidence E10-E14 by 1.9 times (392.3 in 2021 against 207.2 in 2018). Mortality from E10-E14 in Kazakhstan increased during the pandemic by more than 1.5 times (34.1 per 100,000 in 2021 against 22.3 per 100,000 in 2018), and the average survival time at E10-E14 shifted (from 69.8 to 70.5 years) ( = 0.001).
To a greater extent, the increase in diseases and terminal outcomes occurred due to non-insulin-dependent type (E11) diabetes, mainly in the female population.
在新冠疫情期间，糖尿病患者是最脆弱的群体之一。我们的目的是研究哈萨克斯坦在当前疫情之前及期间糖尿病患者的发病率、死亡率和生存率动态。
计算指标时考虑了性别和疾病分类形式（根据国际疾病分类第十版为E10 - E14）。生存分析采用构建生存表的方法和Kaplan - Meier方法。基于这些方法，对2018 - 2021年期间1903243例糖尿病病例和20605例糖尿病死亡的官方报告数据进行了分析。
在哈萨克斯坦，新冠疫情期间，所有疾病病例的绝对频率增加了1.8倍（2021年为716048例，2018年为396990例），新确诊病例增加了2.0倍（从38396例增至75027例），患病率增加了1.7倍（2021年为3743.9，2018年为2142.2），E10 - E14发病率增加了1.9倍（2021年为392.3，2018年为207.2）。哈萨克斯坦E10 - E14的死亡率在疫情期间增加了超过1.5倍（2021年为每10万人34.1例，2018年为每10万人22.3例），E10 - E14的平均生存时间有所变化（从69.8岁变为70.5岁）（P = 0.001）。
在很大程度上，疾病和终末结局的增加主要是由于非胰岛素依赖型（E11）糖尿病，主要发生在女性人群中。
